Antibody Technology Developments (Technical Insights)

Published by: Frost & Sullivan

Published: Sep. 30, 2005 - 117 Pages

Table of Contents

1. Executive Summary
        1. Introduction
                1. Introduction to Antibodies
                2. Overview of Antibody Industry
        2. Scope and Methodology
                1. Scope and Segmentation of the Research Service
                2. Methodology

2. Antibody Technology Overview
        1. Technology Primer
                1. Monoclonal Versus Polyclonal Antibodies
                2. Applications
        2. Innovations in Key Companies and Universities
                1. Emerging Technology Innovations in Companies
                2. Emerging Technology Innovations in Universities

3. Technology Adoption Factor Analysis
        1. Technology Analysis
                1. Restraints
                2. Challenges
                3. Drivers
        2. Influential Market Factors
                1. Corporate Collaborations
                2. Funding Sources

4. Innovative Developments in Antibody Technologies in North America
        1. Companies
                1. Fully Human Proteins from Modified Yeast
                2. New Monoclonal Antibody Delivery and Synthesis Technology
                3. Novel Antibodies for Effective Antimicrobial Therapy
                4. Novel Technology Platforms for Making Monoclonal Antibodies for Cancer and Immunological Diseases
                5. Monoclonal Antibodies for Cancer and Inflammatory Diseases
                6. Transgenic Mice for Production of Fully Human Antibodies
                7. Antigen Based Therapeutic Synthetic Vaccines
                8. Novel Human Antibodies against Cancer
                9. Unique Antibody Based Approach for Disease Diagnosis and Management
                10. Therapeutic Antibodies for Inflammatory and Immunological Diseases
                11. Novel Antibody Array to Study Cytokine Expression Levels
                12. Simple Low Cost Assay for Studying Gene-Protein Interactions
                13. Innovative Technology for Generation of Cancer Therapeutics
                14. Monoclonal Antibodies for Inflammatory Diseases
        2. Academic Institutions
                1. Antibodies as a Cure for Anthrax
                2. Stress Increases Antibody Production in Hybridoma Cells Grown in Culture

5. Innovative Developments in Antibody Technologies in Europe
        1. Companies
                1. Production of Fully Human Antibodies through Human Combinatorial Antibody Libraries
                2. Novel Technology Targets Bacterial Haptens
                3. An Alternative Therapy for Malaria - Antimalarial Antibodies
                4. Antibodies against West Nile Virus
                5. Therapeutic Monoclonal Antibodies through Phage Display Libraries
                6. Antibody Production through Genetic Immunization Technique
        2. Academic Institutions
                1. The CAMPATH Series of Antibodies
                2. Antibodies for Malarial Parasite

6. Innovative Developments in Antibody Technologies in APAC
        1. Companies
                1. Unique Humanization Technology for Producing Antibody Products
                2. Innovative Technology for Producing High Affinity Monoclonal Antibodies
                3. Small Molecule Cytokine Antagonists as Therapy for Inflammatory Disorders
                4. Immunomodulatory Drug as a Treatment for Autoimmune and Inflammatory Disorders
        2. Academic Institutions
                1. Research for Treatment of Miscarriage
                2. Study Shows Evidence of Link between a Common Virus and Breast Cancer

7. Patents and Key Contacts
        1. Patents
                1. Patents I
                2. Patents II
        2. Key Contacts
                1. Companies
                2. Universities

8. Frost & Sullivan 2005 Science and Technology Awards
        1. Excellence in Technology Award
                1. Award Description
                2. Award Recipient
        2. Technology Innovation Award
                1. Award Description
                2. Award Recipient
        3. Excellence in Research Award
                1. Award Description
                2. Award Recipient

9. Critical Reference Tables
        1. Decision Support Databases
                1. Number of Biotech Companies (1999 to 2006)
                2. Private Funding for Research in Biotechnology (1999 to 2006)
                3. Government Funding for Research in Biotechnology (1999 to 2006)
                4. Incidence of HIV and AIDS (1999 to 2006)
                5. Breast Cancer Incidence (1999 to 2006)
                6. Lung Cancer Incidence (1999 to 2006)
                7. Prostate Cancer Incidence (1999 to 2006)
                8. Prevalence of Alzheimer's Disease (1999 to 2006)
                9. Prevalence of Multiple Sclerosis (1999 to 2006)

Abstract

Limited Efficacy of Conventional Therapies Kindle Interest in Antibody Technology

The limited efficacy of conventional therapies, especially in the case of several autoimmune and inflammatory disorders, is creating a strong demand for safe and effective alternate treatments. Considering this, monoclonal antibodies (Mabs) are expected to play a crucial role in facilitating the treatment of not only autoimmune and inflammatory disorders, but also cardiovascular and other infectious diseases. Crucially, in furthering research and overcoming challenges related to the humanization of antibodies of murine origin, technology developers have successfully developed several antibody humanization techniques. These techniques remove the immunogenicity of the murine antibody in humans, thereby solving the problem of human anti-mouse antibodies (HAMA) response.

This Technical Insight study provides insights into developments in antibody technology. It identifies and analyzes emerging technologies and novel applications of existing ones in the context of antibody technology developments. Also, the study endeavors to cover advances in R&D, product development, and the regulatory aspects related to applications of antibodies. Being a global study, the research service has been categorized into findings that fall within the North American, European, and Asia Pacific regions.

Increasing Elderly Population Drives Demand for Immunotherapies

The expected increase in elderly population in industrial nations over the next two decades is likely to be the most important factor driving the demand for immunotherapies. While other autoimmune disorders and age-related illnesses such as arthritis, Alzheimer’s, as well as Parkinson’s are equally affecting the quality of life, the mortality from cancer, diabetes, liver, and kidney diseases still remains high. Considering this, cancer, which has been poorly served by traditional chemotherapies, represents a major area of opportunity for biotech firms to develop immunotherapeutic products.

Among the many advances in antibody technologies, scientists at Jefferson Medical College have used tobacco plants to produce Mabs - tiny guided protein missiles that can target and hunt down cancer cells. The plants promise to provide a cheaper, faster method of producing anticancer antibodies, raising hopes that the technology can one day be used in humans. "Similarly, the Dutch biotechnology firm Crucell N.V recently announced the discovery of a monoclonal antibody against the West Nile virus, which causes a fatal form of encephalitis in humans," says the analyst of this research service. "The company expects that this antibody may provide a route to prophylaxis, providing passive immunity in the event of an outbreak and, possibly, therapy for patients who might otherwise develop encephalitis."

Capital Access Remains Crucial to Furthering Development

Despite decreases in regulatory approval times in the United States and the European Union (EU), there has been a substantial increase in the time biopharmaceuticals spend in clinical development. Hence, considering the high cost of drug development and the length of time it takes to receive drug approvals, access to capital is likely to be critical to furthering research and commercializing subsequent findings. Most firms do not have a product on the market that can be used to generate revenues and are instead dependent on funds from the venture capitals, public equity markets, and strategic alliances used to share development costs and spread risk.

"Although Mab therapies are relatively expensive and often used as second or third-line treatments for diseases, the efficacy and specificity of Mabs make them an important part of the therapeutic landscape," says the analyst. "Several MAbs have already attained more than $1 billion in annual revenues and several others that are at different stages of clinical testing are expected to enter the global market by 2010."

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.